Abstract:Due to low ability to pass through the cell membrane and lack of proof in target delivery in vivo, anti-microRNA oligonucleotide (AMO) has poor target ability to microRNA in the cytoplasm, which results in low AMO targeting efficiency and limits AMO success in vivo application. In this study, AMO-phospholipids conjugates were developed to provide the characteristics of the two phospholipids to self -assemble via hydrophilic AMO and hydrophobic phospholipid tails to overcome the AMO backbone structures and enhance the AMO delivery efficiency. This AMO-phospholipids enveloped nanoparticles was radiolabeled with technetium -99 m (99mTc) for cellular delivery and in vivo imaging. Methods: 99mTc-radiolabeled miR-155 targeted AMO with partial 2 '-O-methyl (2 '-OMe) and phosphorothioate (PS) chemical modification was prepared via the conjugation to N-hydroxysuccinimide derivative of S-acetylmercaptoacetyltriglycine (NHS-MAG3). This radiolabeled AMO is chemically conjugated with phospholipids to form AMO-phospholipid. The AMO-phospholipids served as a component of nanoparticles to embed the hydrophobic part. AMO-phospholipids fused with polycarboxybetaine (PCB) based distearoyl phosphoethanolamine-polycarboxybetaine (DSPE-PCB) modified cationic lipids to form AMO-phospholipidcoated nanoparticles (AMO-NP), which delivered AMO into cytoplasm in vitro and into tumor in vivo. Further, this radiolabeled AMO-NP was confirmed by gel electrophoresis and evaluated for its serum stability, cytotoxicity, inhibitory ability and cellular uptake in HeLa cells, as well as the fluorescent distribution in vitro. Moreover, its distribution and in vivo imaging were performed HeLa tumor -bearing mice after the injection of radiolabeled AMO-NP. Results: The gel electrophoresis of 99mTc labeled AMO-NP showed good conjugation between AMO and 99mTc. It also kept highly stable in human serum. Western blotting results showed that AMO-NP could up -regulate the expression of C/EBP beta protein, one of target proteins of miR-155 in HeLa cells, proving the ability in the specific binding and inhibition. The cellular uptake of 99mTc labeled AMO-NP was significantly higher than that of bare AMO. Furthermore, FAM labeled AMO-NP displayed its ability of specific and effective distribution in tumor cells and a good stability in cellular level. After the system administration, the distribution and in vivo imaging results revealed the significant difference between 99mTc labeled AMO-NP and negative control probe in HeLa tumor xenograft models, which suggested the specific binding and effective delivery ability of 99Tc labeled AMO-NP in vivo. Conclusion: This study supports the effectiveness and efficiency of cellular and in vivo delivery of 99mTc radiolabeled AMO-NP in cervical tumor and suggests a prospective candidate for future tumor imaging.

[In Vivo Imaging of Breast Tumors by a 99mtc Radiolabeled Probe Targeting Microrna-155 in Mice Models].

Noninvasive Visualization of Microrna-155 in Multiple Kinds of Tumors Using a Radiolabeled Anti-Mirna Oligonucleotide

In Vitro Research on MicroRNA-155 Targeted Radiolabeled Oligonucleotide in Breast Cancer Cells

Improved Synthesis and Biological Evaluation of Tc-99m Radiolabeled Amo for Mirna Imaging in Tumor Xenografts

Radiolabeled AMO-phospholipid Enveloped Nanoparticle for Cellular Delivery and in Vivo Imaging in Cervical Cancer Xenografts

Study on in vivo imaging of 99Tcm-hTERT mRNA as antisense molecular probe in breast cancer tumor-bearing nude mice

[In-Vivo Targeted Imaging of Hepatocellular Carcinoma in Nude Mice Using Quantum Dot Probes].

Study on angiogenesis-targeting paramagnetic nanoliposomes in MRI for diagnosis of pulmonary carcinoma

A Mitochondria-targeted AIEgen Labelled with <SUP>18</SUP>F for Breast Cancer Cell Imaging and Therapy

A novel molecular probe:experimental study in vivo in nude mice bearing tumor

[In-Vivo Tumor Imaging by Radiolabeled RNA Probe Targeting Telomerase].

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Identification and Imaging of Mir-155 in the Early Screening of Lung Cancer by Targeted Delivery of Octreotide-Conjugated Chitosan-Molecular Beacon Nanoparticles.

Optimized Preparation of a 99m Tc-Radiolabeled Probe for Tracing MicroRNA

Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection.

Visualizing miR-155 To Monitor Breast Tumorigenesis and Response to Chemotherapeutic Drugs by a Self-Assembled Photoacoustic Nanoprobe

Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model

Noninvasive Visualization Of Rna Delivery With Tc-99m-Radiolabeled Small Interference Rna In Tumor Xenografts

Molecular Imaging of Tumor-Infiltrating Macrophages in a Preclinical Mouse Model of Breast Cancer.